The Latest Cardiac and Vascular News
FRANKLIN LAKES, N.J., Nov. 6, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.402 billion for the fourth fiscal quarter ended September 30, 2018. This represents an increase of 39.0 percent from the prior-year period, which is primarily due to the acquisition of […]
WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that Steve MacKinnon has joined its senior management team as Vice President of Sales, effective immediately. Reporting to the CEO, Mr. MacKinnon will oversee the creation of a U.S. based sales team […]
SANTA CLARA, Calif.–(BUSINESS WIRE)–Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced that new data from the randomized AMBULATE study will be presented in a late-breaking session on new trials in cardiovascular care at Scientific Sessions 2018, the annual medical meeting of the American Heart Association […]
ST. LOUIS PARK, Minn., Nov. 05, 2018 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, announced today that it has completed a $25 million Series D equity financing. Proceeds from the financing […]
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced new clinical data describing mavacamten’s effect on diastolic function will be presented at the upcoming American Heart Association (AHA) Scientific Sessions […]
WESTMINSTER, Colo., Nov. 05, 2018 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that data from the Atrial Fibrillation Burden (AFB) substudy of the Phase 2B GENETIC-AF clinical trial have been selected for a poster presentation […]
COPENHAGEN, Denmark, November 5, 2018 /PRNewswire/ — – Phase 1 data show favourable safety profile – Data support further development of AP30663 for cardioversion therapy Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces positive results from the Phase 1 clinical trial of its […]
WILMINGTON, Mass., Nov. 5, 2018 /PRNewswire/ — Micro Medical Solutions (MMS), an innovator in the field of microvascular interventions designed to improve clinical outcomes and quality of life, announced today that it has received CE Mark approval for a 4Fr.-compatible MicroStent 120 cm delivery catheter, as well as MicroStent devices in five […]
TRONDHEIM, Norway–(BUSINESS WIRE)–CardioMech AS announced today that it has appointed Richard Nehm as President and CEO, and Mark Novotny as Chairman of the Board of Directors, effective immediately. Rick and Mark join the company alongside founders Jacob Bergsland, Chief Medical Officer, and Nikolai Hiorth, Chief Technology Officer. Rick Nehm is a seasoned medical device professional in the […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2018 financial results. “We are pleased with our third quarter performance and building track record of strong, consistent, revenue growth,” said Mike Carrel, President and Chief […]
